Aberdeen biopharmaceutical start-up EnteroBiotix has appointed a new chief executive officer as it progresses towards commercialisation of its products.
Senior biotechnology executive Dr James Clark becomes CEO, with founder Dr James McIlroy moving to the role of chief business officer.
Founded in 2017 by Dr McIlroy, EnteroBiotix develops faecal derived products for patients suffering from diseases associated with bacterial imbalances in the intestinal gut.
Its novel medicinal products build on the clinically proven strategy of faecal microbiota transplantation (FMT). FMT is the process of transferring bacteria from the gut of a healthy donor into the gut of a recipient to restore a healthy balance.
That same year EnteroBiotix secured a £500,000 seed round led by angel syndicate, Equity Gap, and the Scottish Investment Bank, the investment arm of Scottish Enterprise. The company expects to close a Series A round in the third quarter of this year.
Read more HERE.
